Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Drug Commercials—How Are They Still a Thing?

Philip Seo, MD, MHS  |  Issue: July 2018  |  July 19, 2018

Tero Vesalainen / shutterstock.com

Tero Vesalainen / shutterstock.com

Picture this: It’s 3 o’clock in the morning. You can’t sleep. You settle in front of the television to watch a rerun of Dirty Dancing. And then it hits you: Ask your doctor.

Even as your eyelids sag, some part of your primitive forebrain snaps to attention. Medical training has turned us all into multitaskers, and even as some part of you is desperately trying to fall asleep, another part of your brain has just woken up.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Then you hear it: Not to be used if you have a history of myocardial infarction or stroke. Some patients may experience a paradoxical worsening in their symptoms. Use with caution if you have a history of major depressive disorder or bipolar disorder.

Then the refrain hits: Ask your doctor.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Then you see it: Happy people, laughing at a picnic, on the beach or at a touch football game, with sunlight streaming down. Meaningful looks are exchanged. More smiles ensue. Clearly, something good is happening here, but what?

That is a little harder to discern, because you only started paying attention to the commercial when the anonymous announcer started to rattle off, in rapid succession, all of the medical diagnoses and issues that stand between you and that happy ending. If only you could take this pill, happiness could be yours.

John Oliver, host of the eponymous show on HBO, has an intermittent feature that he calls “How Is This Still a Thing?” He uses this feature to focus on anachronisms or oddities of American culture that persist, despite our inclination to think of ourselves as enlightened. Daylight saving time, which causes us to gain, and then lose, an hour of sleep every year. The penny, which serves to provide commerce with a level of precision that nobody wants. Columbus Day, which celebrates the man who did not discover America.

How Is This Still a Thing?

That catchphrase leaps to my mind every time I see a commercial for a drug on network television. Before my publishing overlords get too worked up, let me mention that I am not objecting to pharmaceutical advertising that targets physicians, such as the ads that appear throughout these pages. Outside my personal gratitude for their support, which enables this publication to exist, this sort of targeted advertising makes sense to me. Not only are these drugs directly relevant to my practice, I also have the ability to understand what the ad means, beyond the glossy pictures of antibodies and glorious sunsets.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:patient communicationpatient management

Related Articles

    Advertise This

    March 18, 2011

    Medical marketing is an interesting place; beware inaccurate claims

    Pharma awaits FDA Guidance to Navigate the Murky Waters of Ads Via the Internet and Social Media

    November 1, 2010

    There’s no question that direct-to-consumer (DTC) advertising of prescription drugs is a huge activity, with nearly $5 billion spent on DTC ads in 2007. There’s also no question that the Internet has a vast potential to reach consumers. But when you put DTC advertising and the Internet together, there is a potential for problems and…

    U.S. Doctor Group Calls for Ban on Drug Advertising to Consumers

    November 19, 2015

    (Reuters)—The American Medical Association on Tuesday called for a ban on advertising prescription drugs and medical devices directly to consumers, saying the ads drive patients to demand expensive treatments over less costly ones that are also effective. The influential doctors’ group said the new policy reflects physicians’ concerns that marketing spending on a proliferation of…

    The Impact of U.S. Supreme Court Decisions on Medical Affairs, Healthcare Policy

    October 11, 2016

    As America’s capital, Washington, D.C., maintains an outsized influence in our daily lives. Despite having a meager sliver of the New York City population, the daily political transactions that transpire in the District of Columbia impact our lives. The comings and goings in the corridors of Congress are likely to have a greater impact on us…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences